Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/wnl.57.6.1139 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interventions for preventing weight gain after smoking cessation.
Cochrane Database Syst Rev
October 2021
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Background: Most people who stop smoking gain weight. This can discourage some people from making a quit attempt and risks offsetting some, but not all, of the health advantages of quitting. Interventions to prevent weight gain could improve health outcomes, but there is a concern that they may undermine quitting.
View Article and Find Full Text PDFFenfluramine repurposing from weight loss to epilepsy: What we do and do not know.
Pharmacol Ther
October 2021
Division of Clinical and Experimental Pharmacology, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
In 2020, racemic-fenfluramine was approved in the U.S. and Europe for the treatment of seizures associated with Dravet syndrome, through a restricted/controlled access program aimed at minimizing safety risks.
View Article and Find Full Text PDFPharmacological and non-pharmacological strategies for obese women with subfertility.
Cochrane Database Syst Rev
March 2021
Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Background: Clinicians primarily recommend weight loss for obese women seeking pregnancy. The effectiveness of interventions aimed at weight loss in obese women with subfertility is unclear.
Objectives: To assess the effectiveness and safety of pharmacological and non-pharmacological strategies compared with each other, placebo, or no treatment for achieving weight loss in obese women with subfertility.
Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling.
Int J Mol Sci
June 2020
Laboratory of Cardiology, GIGA Cardiovascular Sciences, University of Liège, 4000 Liège, Belgium.
Several clinical reports indicate that the use of amphetaminic anorectic drugs or ergot derivatives could cause valvular heart disease (VHD). We sought to investigate whether valvular lesions develop in response to long-term oral administration of these drugs and to identify drug-targeted biological processes that may lead to VHD. Treatment of New Zealand White rabbits with pergolide, dexfenfluramine, or high-dose serotonin for 16 weeks induced valvular alterations characterized by extracellular matrix remodeling.
View Article and Find Full Text PDFFluoxetine for adults who are overweight or obese.
Cochrane Database Syst Rev
October 2019
Clinical Nutrition, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, Mexico City, Distrito Federal, Mexico, 14000.
Background: Fluoxetine is a serotonin reuptake inhibitor indicated for major depression. It is also thought to affect weight control: this seems to happen through appetite changes resulting in decreased food intake and normalisation of unusual eating behaviours. However, the benefit-risk ratio of this off-label medication is unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!